Ascend Advanced Therapies Successfully Defends EpyQ® Patent at EPO

On October 8, 2025, Ascend Advanced Therapies announced a significant victory in defending its European patent EP3722434. This patent protects the company's proprietary EpyQ® AAV plasmid technology, which faced opposition proceedings at the European Patent Office (EPO). The successful defense confirms the novelty and strength of Ascend's approach in AAV plasmid design and production.

Opposition proceedings at the EPO are known for their rigorous challenge to patent validity. Thus, the decision to uphold Ascend's patent underscores the robustness of its intellectual property. Markus Hörer, Chief Scientific Officer of Ascend, highlighted the importance of this achievement in reinforcing their leadership in AAV plasmid technology.

The sustained patent provides a solid foundation for advancing EpyQ® technology in gene therapy. Ascend remains committed to offering innovative AAV plasmid solutions that drive progress in genetic medicine.